Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards on March 3, 2026 under its 2024 Inducement Plan to six new employees. The grants include 46,000 non‑qualified stock options and 25,875 RSUs.
Options have an exercise price of $39.30 (closing price on March 3, 2026); options and RSUs vest over four years with 25% after one year and remaining vesting monthly or on annual anniversaries (Feb 20 or May 20, 2026) as applicable.
Vera Therapeutics (Nasdaq: VERA) appointed Christopher Hite to its Board of Directors effective March 5, 2026. Mr. Hite will serve as an independent director and brings over 25 years of strategic and financial leadership in biopharma, currently serving as Executive Vice President and Vice Chairman at Royalty Pharma.
The appointment coincides with Vera Therapeutics preparing for the potential launch of its dual BAFF/APRIL inhibitor atacicept for IgA nephropathy later in 2026, and management says Hite will support the company’s commercial and financial strategy.
Vera Therapeutics (NASDAQ: VERA) reported full-year 2025 results and a business update. Positive ORIGIN Phase 3 atacicept data were presented at ASN and published in NEJM, and the FDA granted priority review with a PDUFA date of July 7, 2026.
The company plans a potential mid-2026 U.S. commercial launch if approved. Vera completed equity and debt financings with combined potential gross proceeds of $800 million, and held $714.6 million in cash, equivalents and marketable securities at 12/31/2025. Net loss was $299.6 million for 2025.
Vera Therapeutics (Nasdaq: VERA) will present at multiple investor conferences in March 2026, including a TD Cowen fireside chat and one-on-one investor meetings at Barclays and Jefferies events.
The TD Cowen fireside chat is webcast on March 3, 2026 at 11:10am ET; a replay will be available for 90 days via the company’s Investor Calendar.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted on February 2, 2026 to two new employees under its 2024 Inducement Plan. The Compensation Committee granted non‑qualified stock options for 11,500 shares and RSUs for 5,750 shares.
Each option’s exercise price equals $45.28 (closing price on February 2, 2026). Options vest over four years with 25% after one year then monthly over 36 months; RSUs vest 25% on each anniversary of February 20, 2026, subject to continued service and plan terms.
Vera Therapeutics (Nasdaq: VERA) named Matt Skelton Chief Commercial Officer, effective January 28, 2026. Skelton, previously Executive Vice President, Commercial, joined Vera over a year ago and will lead launch readiness for atacicept targeting IgA nephropathy.
Skelton’s background includes scaling Seagen’s commercial organization to four approved products and senior commercial roles at Amgen and Eli Lilly.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted January 5, 2026 to 18 new employees under its 2024 Inducement Plan.
The Compensation Committee granted non-qualified stock options to purchase 228,750 shares and restricted stock units underlying 116,000 shares. Each option has an exercise price of $47.07, equal to the closing price on January 5, 2026.
Options vest over four years (25% at one year, then monthly over 36 months) subject to continued service; RSUs vest 25% on each anniversary of February 20, 2026 over four years. Awards are subject to the Inducement Plan and award agreements.
Vera Therapeutics (NASDAQ:VERA) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 2:15 PM PST.
The team will participate in one-on-one investor meetings and provide a live webcast at the conference link. A replay will be available for 90 days via the company's Investor Calendar.
Vera Therapeutics (NASDAQ: VERA) announced the U.S. FDA accepted its BLA for atacicept in adults with immunoglobulin A nephropathy (IgAN) and granted Priority Review with a PDUFA target action date of July 7, 2026.
The submission used the Accelerated Approval Program and follows Breakthrough Therapy designation. A prespecified interim analysis from the ORIGIN 3 trial showed atacicept reduced proteinuria by 46% from baseline and by 42% versus placebo (p<0.0001) at week 36. Results were presented at ASn Kidney Week and published in the New England Journal of Medicine on November 6, 2025. If approved, atacicept could be offered as a once-weekly subcutaneous autoinjector for at-home use.
Vera Therapeutics (NASDAQ: VERA) priced an underwritten public offering of 6,138,108 Class A shares at $42.50 per share, expected to raise approximately $261 million in gross proceeds before fees.
The company granted underwriters a 30-day option to buy up to an additional 920,716 shares at the public offering price. The offering is expected to close on December 11, 2025, subject to customary closing conditions. Joint book-runners include J.P. Morgan, Goldman Sachs, Evercore ISI and Cantor; LifeSci Capital is lead manager.